TrialNature communications2025

Neoadjuvant with low-dose radiotherapy, tislelizumab, albumin-bound paclitaxel, and cisplatin for resectable locally advanced head and neck squamous cell carcinoma: phase II single-arm trial.

Zhigang Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.